Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort - PubMed
5 days ago
- #Chemoradiotherapy
- #EGFR-mutated NSCLC
- #Osimertinib
- Osimertinib showed significant improvement in progression-free survival (PFS) vs. placebo in unresectable stage III EGFR-mutated NSCLC patients post-chemoradiotherapy (CRT).
- The LAURA China cohort (19% of global participants) demonstrated a median PFS not reached for osimertinib vs. 3.7 months for placebo.
- Objective response rate (ORR) was 63% for osimertinib vs. 15% for placebo, with manageable safety profile and no treatment discontinuations due to adverse events.
- Findings support osimertinib as the new standard of care post-CRT for this patient group, both globally and in China.